Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$43.83
-$0.69(-1.21%)
At close: 4:00 PM EST
$43.83
-$0.69(-1.21%)
Day’s Range― - ―
52-Week Range$42.96 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)17.07M
Market Cap
$89.21B
Enterprise Value$131.71B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$50.93B
Price to Earnings (P/E)17.7
Beta0.27
Next Earnings
Oct 30, 2025EPS Estimate
1.54Last Dividend Ex-Date
Oct 03, 2025Dividend Yield5.66%
Share Statistics
EPS (TTM)1.46
Shares Outstanding2,035,435,800
10 Day Avg. Volume13,892,116
30 Day Avg. Volume17,070,328
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.48
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda8.73
Forecast
1Y Price Target
$51.00Price Target Upside16.36% Upside
Rating ConsensusHold
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessBMY recently reported positive top-line MRD-negativity data from the Ph3 EXCALIBER-RRMM trial of Iberdomide.
New Product LaunchesThe I/O and hematology businesses are producing stable cash flows and new launch products are continuing to ramp.
Pipeline PotentialUpcoming catalysts in 2025/2026, including phase 3 readouts for Cobenfy in Alzheimer’s disease psychosis, are anticipated.
Bears Say
Growth ChallengesFacing dual headwinds of ongoing/near-term LOEs and several recent pipeline setbacks, investors are still looking for clarity on the path back to sustainable growth.
Product PerformanceCobenfy TRx decreased -4.7% WoW to 2,211 TRx, giving less confidence in Cobenfy beating estimates in 3Q.
Stock PerformanceBMY stock down -23% ytd (vs. pharma +3%), this will be an important earnings call to set the stage for 2026.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.96 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $89.21B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 30, 2025 which is in 3 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Aug 01, 2025. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.091 by $0.369.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 5.66%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.54.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,435,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.46 in its last earnings report, beating expectations of $1.091. Following the earnings report the stock price went up 2.13%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.00 (16.36% Upside)
$51.00 (16.36% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 350.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.05%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates in various therapeutic areas, including oncology, immunology, cardiovascular, and fibrosis, with a strong portfolio of pharmaceuticals and biologics. Core products include well-known drugs such as Opdivo, Eliquis, and Revlimid. BMY is committed to advancing science through research and collaborations to address unmet medical needs.
BMY Company Deck
BMY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the growth portfolio and successful strategic initiatives, with increased revenue and earnings guidance. Despite challenges in the legacy portfolio and some study outcomes not meeting expectations, the company is well-positioned for long-term growth with a robust pipeline and strategic partnerships.View all BMY earnings summariesBMY Revenue Breakdown
53.29% Legacy Portfolio
46.71% Growth Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$51.00
▲(16.36% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
22.75% Mutual Funds
0.33% Other Institutional Investors
51.38% Public Companies and Individual Investors